Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 571 | PfizerINDUSTRY | 27 | Jul 27, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00145626 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies |
| completed |
| Phase 2 |
| 40 |
| St. Jude Children's Research HospitalOTHER |
| 1 |
| Jun 19, 2017 |
| clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00408681 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant(GVHD) | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01126892 | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | completed | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00815321 | Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy | completed | Phase 2 | 11 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02977312 | Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan(CCMLJ) | completed | — | 91 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT00845221 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | completed | Phase 4 | 44 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT01252589 | Patient Reported Outcomes in Chronic Myeloid Leukemia | completed | — | 480 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 10 | Sep 14, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT01394666 | Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) | completed | — | 150 | Bristol-Myers SquibbINDUSTRY | 0 | Jul 11, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01056614 | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies | completed | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00428909 | Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 21, 2016 | clinicaltrials |
| NCT00750659 | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02733445 | Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | completed | — | 2,650 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 11, 2016 | clinicaltrials |
| NCT01275196 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | completed | Phase 3 | 267 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT01019317 | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00303290 | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00866736 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | completed | Phase 2 | 65 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01342679 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib(CMR-CML) | completed | Phase 2 | 21 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01805843 | Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia | completed | — | 16 | Medical University of GrazOTHER | 1 | Sep 9, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT02363868 | Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | completed | — | 186 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01795716 | Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body | completed | Phase 1 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 19, 2015 | clinicaltrials |
| NCT01220648 | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)(NICOLI) | completed | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2015 | clinicaltrials |
| NCT02016833 | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | completed | — | 15 | PX BiosolutionsINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2017source: clinicaltrials